达夫尼丁调节GLP-1R以缓解糖尿病患者的认知功能障碍:对炎症和氧化应激的影响
Feng Liang1, Xinyi Tian2, Lining Ding2,3
1Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province Wenzhou, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
Frontiers in pharmacology
|September 11, 2024
概括
达夫尼丁通过作为GLP-1R激动剂来缓解糖尿病认知功能障碍,减少炎症和氧化应激. 这表明达芬尼对于预防2型糖尿病认知问题有价值.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病认知功能障碍是有限的治疗选择越来越令人担忧.
- 达夫尼丁显示出药理学效应,但其在糖尿病认知功能障碍中的作用尚不清楚.
- 葡萄糖类-1受体 (GLP-1R) 涉及代谢和神经功能.
研究的目的:
- 调查达芬尼在减轻糖尿病认知功能障碍中的作用.
- 探索GLP-1R途径对达芬尼影响的参与.
- 为了确定达芬尼丁是否作为GLP-1R激动剂.
主要方法:
- 在糖尿病老鼠和PC12细胞中进行了药理学研究.
- 测量了GLP-1R的表达水平.
- 评估了炎症和氧化应激标志物.
- 用GLP-1R的抑制和过度表达来阐明其作用.
主要成果:
- 达夫尼丁在体内和体外减轻了糖尿病认知功能障碍.
- 达夫尼丁治疗增加了GLP-1R的表达.
- 达芬尼丁的保护作用与减少炎症和氧化应激有关.
- 抑制GLP-1R增强了达芬尼的保护作用,而过度表达则削弱了它们.
结论:
- 达夫尼丁通过调节GLP-1R介导的炎症和氧化应激,保护糖尿病的认知功能障碍.
- 达夫尼作为GLP-1R激动剂起作用.
- 达夫尼丁具有重要的治疗潜力,可以预防2型糖尿病的认知功能障碍.
- GLP-1R被确定为相关疾病的关键治疗标.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K


